First new prescription treatment approved for smoking cessation in nearly a decade, received priority review designation by FDA. Addiction to nicotine is a chronic medical condition that makes quitting smoking difficult. Chantix is a breakthrough treatm
Titration can reduce Nausea from Chantix
Published on September 15, 2006 By know-chantix In Health & Medicine
There are two basic elements to deal with when someone quits the smoking habit: The physical addiction and the mental addiction.
The physical addiction of smoking is the result of the body's addiction to nicotine. When people stop smoking, the body exhibits withdrawal symptoms such as jitters, headaches, and irritability. This leads us to the second element: mental addiction.

Quitting smoking will:
Help to live longer and live better.
Lower chances of having a heart attack, stroke, or cancer.
Improve chances of having a healthy baby.
The people you live with, especially your children, will be healthier.
Have extra money to spend on things other than cigarettes.

According to an article published in the Archives of Internal Medicine, more evidence indicates that Chantix (varenicline) is effective and safe when used to help smokers quit.

The Centers for Disease Control (CDC) estimate that 44.5 million people in the U.S. are smokers, and approximately 8.6 million of these individuals currently have a chronic disease that is directly related to smoking. Smoking cessation is a critical part of improving the health of these individuals.

Chantix is a medication that binds to and partially activates nicotine receptors in the brain. This partial activity reduces nicotine withdrawal symptoms. In addition, because Chantix blocks nicotine from binding to its receptors, use of Chantix may diminish the pleasure derived from smoking. These effects may make it easier for smokers to quit.

Many patients taking Chantix (varenicline tartrate) to help kick the smoking habit could be spared the side effect of nausea if introduced to the drug gradually.
During treatment, 42% of the non-titrated 1.0 mg group became nauseated, versus 34% of the 1.0 mg titrated group.
Titrating the dose of Chantix during the first week of treatment led to a drop of six to seven percentage points in the proportion of patients who became nauseated.

Comments
No one has commented on this article. Be the first!